Lipomics Technologies enters agreement with Isis Pharmaceuticals to provide lipid-focused support of preclinical and clinical trial testing for various compounds to treat metabolic disease
Lipomics will retain exclusive rights to develop diagnostic applications based on the data from the studies, while Isis will retain all therapeutic rights.
Lipomics seeks to partner with drug companies that see the value in developing companion diagnostic tests that increase the efficacy, safety and cost-effectiveness of a therapeutic.
Sanjay Bhanot, vice president, metabolic diseases R+D at Isis, commented: "We are impressed with Lipomics's capabilities and look forward to working with it as we assess the lipid profiles of compounds we have in our metabolic disease development pipeline".
"We look forward to working with Isis.
"We believe our approach, which focuses on providing plasma-based mechanistic markers of lipid metabolism, will help to advance their compounds through the clinic," said Steve Watkins, president and chief scientific officer at Lipomics.
